Effects of Ivabradine on Cardiac Circulation in patients with Angina

Phase 4

• Conditions: Chronic Stable Angina; C14.280.647

• Registration Number: RBR-5fysqrh
• Lead Sponsor: Medicina Nuclear do Alto da XV

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-11-14
• Study Start: 2023-11-30
• Last Update Posted: 19 December 2023

Recruitment & Eligibility

• Status: Recruitment completed
• Sex: Not specified
• Target Recruitment: Not specified

Inclusion Criteria

Patients with chronic stable angina pectoris; aged between 18 and 70 years; who remain symptomatic despite of using beta blockers (maximum tolerated dose) and HR = 70 bpm; sinus rhythm; LVEF >40%; and any ischemia in baseline myocardial perfusion scintigraphy; performed with a physical stress test; in accordance with previous drug therapy

Exclusion Criteria

Unstable angina; Myocardial infarction <6 months; LVEF <40%; HR <70 bpm; presence of left bundle branch block; pacemaker; patients who cannot perform a treadmill stress test (physical limitation); pregnancy, breastfeeding or women in childbearing age who are not taking appropriate contraceptive methods; patients with hypersensibility to ivabradine or any component of the formula, cardiogenic shock, acute myocardial infarction, severe hypotension; and patients with contraindication to perform a myocardial scintigraphy.And also strict precautions (ie contraception) are needed in women of childbearing potential (because ivabradine and scintigraphy)

Study & Design

• Study Type: Intervention
• Study Design: Not specified